GSK plc (GSK)'s Asthma Drug Gets FDA Nod to Treat 'Smoker's Lung'
The FDA approved GSK's asthma drug, Nucala, for treating a type of COPD, expanding its use as an add-on therapy. The medication targets interleukin-5 to reduce lung inflammation. GSK highlighted the increasing burden of COPD-related hospitalizations on the healthcare system.